IL-6 and its receptors in coronary artery disease and acute myocardial infarction

Cytokine

Volumn 62, Issue 3, 2013, Pages 395-400

  Anderson, Daniel R ^a,b   Poterucha, Joseph T ^b   Mikuls, Ted R ^a,c   Duryee, Michael J ^a,c   Garvin, Robert P ^b   Klassen, Lynell W ^a,c   Shurmur, Scott W ^b   Thiele, Geoffrey M ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Department of Internal Medicine   (United States)

^c VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Acute coronary syndromes; Acute myocardial infarction; Glycoprotein 130; Interleukin 6; Soluble interleukin 6 receptor

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE; CREATINE KINASE MB; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; MESSENGER RNA; SOLUBLE INTERLEUKIN 6 RECEPTOR; TRIACYLGLYCEROL; TROPONIN I; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR;

ACUTE HEART INFARCTION; ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR BINDING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; HEART INFARCTION; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS;

C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CYTOKINE RECEPTOR GP130; DEMOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; MYOCARDIAL INFARCTION; RECEPTORS, INTERLEUKIN-6; REGRESSION ANALYSIS;

EID: 84877813326     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.03.020     Document Type: Article

References (31)

1. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:948-954.
2. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
3. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91:281-291.
4. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
6. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
7. Miyao Y., Yasue H., Ogawa H., Misumi I., Masuda T., Sakamoto T., et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993, 126:1299-1304.
8. Corbi P., Rahmati M., Delwail A., Potreau D., Menu P., Wijdenes J., et al. Circulating soluble gp130, soluble IL-6R, and IL-6 in patients undergoing cardiac surgery, with or without extracorporeal circulation. Eur J Cardiothorac Surg 2000, 18:98-103.
9. Narazaki M., Yasukawa K., Saito T., Ohsugi Y., Fukui H., Koishihara Y., et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993, 82:1120-1126.
10. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011, 1813:878-888.
11. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993, 90:11924-11928.
12. Luchtefeld M., Preuss C., Ruhle F., Bogalle E.P., Sietmann A., Figura S., et al. Gp130-dependent release of acute phase proteins is linked to the activation of innate immune signaling pathways. PLoS One 2011, 6:e19427.
13. Gillum R.F., Fortmann S.P., Prineas R.J., Kottke T.E. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 1984, 108:150-158.
14. Ueda K., Takahashi M., Ozawa K., Kinoshita M. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction. Am Heart J 1999, 138:908-915.
15. Andersson J., Libby P., Hansson G.K. Adaptive immunity and atherosclerosis. Clin Immunol 2010, 134:33-46.
16. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999, 19:2348-2354.
17. Bhakdi S., Torzewski M., Paprotka K., Schmitt S., Barsoom H., Suriyaphol P., et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004, 109:1870-1876.
18. Buerke M., Prufer D., Dahm M., Oelert H., Meyer J., Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther 1998, 286:429-438.
19. Buono C., Come C.E., Witztum J.L., Maguire G.F., Connelly P.W., Carroll M., et al. Influence of C3 deficiency on atherosclerosis. Circulation 2002, 105:3025-3031.
20. Schmiedt W., Kinscherf R., Deigner H.P., Kamencic H., Nauen O., Kilo J., et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998, 18:1790-1795.
21. Turnberg D., Botto M., Lewis M., Zhou W., Sacks S.H., Morgan B.P., et al. CD59a deficiency exacerbates ischemia-reperfusion injury in mice. Am J Pathol 2004, 165:825-832.
22. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001, 158:1039-1051.
23. Atreya R., Mudter J., Finotto S., Mullberg J., Jostock T., Wirtz S., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000, 6:583-588.
24. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
25. Hurst S.M., Wilkinson T.S., McLoughlin R.M., Jones S., Horiuchi S., Yamamoto N., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14:705-714.
26. Nowell M.A., Williams A.S., Carty S.A., Scheller J., Hayes A.J., Jones G.W., et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 2009, 182:613-622.
27. Snyers L., Content J. Enhancement of IL-6 receptor beta chain (gp130) expression by IL-6, IL-1 and TNF in human epithelial cells. Biochem Biophys Res Commun 1992, 185:902-908.
28. Lenegre J. Etiology and pathology of bilateral bundle branch block in relation to complete heart block. Prog Cardiovasc Dis 1964, 6:409-444.
29. Luchtefeld M., Schunkert H., Stoll M., Selle T., Lorier R., Grote K., et al. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J Exp Med 2007, 204:1935-1944.
30. Kakouros N., Cokkinos D.V. Right ventricular myocardial infarction: pathophysiology, diagnosis, and management. Postgrad Med J 2010, 86:719-728.
31. Aoyama T., Takimoto Y., Pennica D., Inoue R., Shinoda E., Hattori R., et al. Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. J Mol Cell Cardiol 2000, 32:1821-1830.